gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
gptkbp:brand
|
gptkb:Aduhelm
|
gptkbp:chemical_formula
|
C6480 H10000 N1710 O2000 S44
|
gptkbp:class
|
gptkb:immunotherapy
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
Phase 3
|
gptkbp:clinical_trial_end_year
|
gptkb:2019
|
gptkbp:clinical_trial_start_year
|
gptkb:2015
|
gptkbp:collaborations
|
collaboration with universities
collaboration with research institutes
|
gptkbp:competitors
|
gptkb:Donanemab
gptkb:Lecanemab
|
gptkbp:controversy
|
high cost
efficacy debate
|
gptkbp:developed_by
|
gptkb:Biogen
|
gptkbp:discovery_year
|
gptkb:2012
|
gptkbp:dosage_form
|
solution for infusion
|
gptkbp:duration
|
monthly
|
gptkbp:effective_date
|
gptkb:2021
FDA approved
|
gptkbp:funding
|
public and private funding
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aducanumab
|
gptkbp:indication
|
mild cognitive impairment
mild Alzheimer's disease
|
gptkbp:invention
|
patented
|
gptkbp:is_monitored_by
|
recommended during treatment
|
gptkbp:knockouts
|
high affinity for amyloid beta
|
gptkbp:launch_date
|
gptkb:2021
|
gptkbp:marketed_as
|
Biogen and Eisai
|
gptkbp:mechanism_of_action
|
reduces amyloid plaques
|
gptkbp:patient_eligibility_criteria
|
age criteria
biomarker confirmation
specific cognitive impairment
|
gptkbp:patient_population
|
Alzheimer's patients
|
gptkbp:phase3_trial_name
|
EMERGE
ENGAGE
|
gptkbp:provides_guidance_on
|
included in Alzheimer's treatment guidelines
|
gptkbp:publication
|
published in peer-reviewed journals
|
gptkbp:regulatory_body_approval
|
gptkb:FDA
gptkb:EMA
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
|
gptkbp:route_of_administration
|
intravenous
|
gptkbp:service_frequency
|
every 4 weeks
|
gptkbp:side_effect
|
dizziness
headache
nausea
confusion
brain swelling
required by FDA
|
gptkbp:storage
|
refrigerated
|
gptkbp:targets
|
amyloid beta
|
gptkbp:used_for
|
gptkb:neurodegenerative_diseases
|
gptkbp:weight
|
146 k Da
|
gptkbp:bfsParent
|
gptkb:Biogen
|
gptkbp:bfsLayer
|
4
|